Earnings call transcript: Stryker Q1 2026 results miss forecasts amid cyber incident

Stryker’s Q1 2026 earnings missed expectations, with EPS of $2.60 vs. $2.98 consensus and revenue of $6.0B vs. $6.34B, as a cyber incident disrupted operations for roughly three weeks. Management maintained full-year guidance for 8%-9.5% organic sales growth and $14.90-$15.10 adjusted EPS, citing recovery in Q2 and the back half of the year. Offset to the miss, Mako installations hit a Q1 record, international growth remained strong, and the stock slipped 0.2% after hours to $314.51.

Analysis

The market is still treating this as a one-quarter earnings miss, but the bigger signal is that Stryker proved the cyber event was an execution shock, not a demand shock. That matters because the company’s mix has a built-in self-healing mechanism: consigned inventory and recurring consumables should normalize much faster than made-to-order capital, so the earnings catch-up is likely to be back-half loaded rather than linear. The immediate loser is not just Stryker’s near-term margin, but any vendor that competes on response time in hospital capital and procedural workflow; once customers experience a supply interruption, procurement teams tend to widen vendor panels as a hedge, which can pressure replacement-cycle loyalty.

The more interesting second-order effect is competitive positioning. If Stryker keeps its guide intact while recovering shipment timing, it strengthens the narrative that its platform is resilient enough to absorb operational shocks without losing share, which is bad news for smaller orthopedic and medtech rivals that need clean quarters to defend valuation multiples. However, the cyber event also exposes a hidden risk: the company is now under more scrutiny on business continuity, so any follow-on IT hiccup over the next 1-2 quarters would be punished disproportionately because investors will have reset expectations for "normalization."

The contrarian view is that the selloff is likely overdone if the market is pricing a permanent haircut to 2026 rather than a timing shift. The setup favors a recovery trade over a structural short: the path to upside is Q2/Q3 revenue catch-up plus multiple repair if management shows no share loss, while the downside is mostly limited to another round of evidence that recovery is slower than promised. The key catalyst is the next quarterly print, where investors will focus less on reported growth and more on whether deferred procedures and delayed capital shipments are actually flowing back as claimed.

Key Decisions for Investors

• Go long SYK over the next 1-2 weeks on any post-earnings weakness; risk/reward favors a 5-8% rebound if Q2 shows even partial catch-up and no share leakage.
• Structure a SYK call spread into the next earnings cycle (e.g., 1-2 quarter horizon) to express recovery without paying full vol; upside is a normalization rerate, downside capped if the catch-up drags.
• Pair trade: long SYK / short a smaller-cap orthopedic or medtech peer with weaker balance-sheet flexibility and less recurring revenue; the cyber incident should widen competitive dispersion over the next 1-2 quarters.
• Avoid shorting SYK here unless there is evidence of lost accounts or a second operational issue; the setup is more likely a timing unwind than a durable fundamentals break.
• Watch for an entry add after the next quarter if management demonstrates back-half revenue catch-up; if recovery is visible, the stock can rerate before full-year numbers are fully visible.